AVADEL PHARMACEUTICALS PLC — Director's Dealing 2025

Jul 31, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AVADEL PHARMACEUTICALS PLC (AVDL)
CIK: 0001012477
Period of Report: 2025-07-29

Reporting Person: Amin Naseem (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-07-29	Ordinary Shares	A	11000	—	Acquired	22000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-07-29	Stock Option (Right to Buy)	$10.83	A	11000	Acquired	2035-07-29	Ordinary Shares (11000)	Direct

Footnotes

F1: Represents a restricted share award. The shares shall vest in full on the earlier to occur of (a) July 29, 2026 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time.

F2: The options shall vest in full on the earlier to occur of (a) July 29, 2026 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time.